Jean-Louis Dasseux, Ph.D., M.B.A.
President and CEO, Cerenis Therapeutics
A co-founder of Cerenis and is one of the world’s leading experts in lipid metabolism and lipid-protein interaction. He was the inventor of a high-capacity reverse lipid transport peptide (ETC-642) and a series of small molecule compounds that raise HDL levels. Dr. Dasseux was formerly Vice President of Chemistry and Technology at Esperion Therapeutics. Before joining Esperion, he was Director of Research for the French pharmaceutical company Fournier, where he established and managed its research center in Heidelberg, Germany.
Chief Medical Officer
Dr. Renée Benghozi is an international clinical specialist in the development of pharmaceutical products for the treatment of cardiovascular and metabolic diseases. She has spent more than fifteen years at F. Hoffmann-La Roche Ltd. where she was recently the International Medical Director. Her past career in clinical medicine and her substantial experience in the pharmaceutical industry with the cardiology patients are also extremely valuable regarding her critical management role in drug development at Cerenis.
Constance Keyserling, M.S.
Sr. Vice President, Clinical Development
Ms. Keyserling has more than 20 years of global clinical development experience at Parke-Davis, Pfizer, Esperion, and QuatRx. She was previously Vice president of Development Operations at QuatRx. Prior to that, Ms. Keyserling was senior director of operations at Esperion, where her responsibilities included clinical program design and management, clinical outsourcing, regulatory operations and SOP systems development.
Cyrille Tupin, C.P.A.
Vice President, Finance
Mr. Tupin previously was Audit Director of Sygnatures, the largest private audit and consultant company in Toulouse, France. Prior to that, Mr. Tupin spent more than seven years with PricewaterhouseCoopers. He has worked on a number of high-profile business transactions including the Alcan Group takeover bid for Pechiney and the consolidation audit of Pechiney for Alcan. Mr. Tupin has been a French CPA since 2002.
Ronald Barbaras, Ph.D.
Senior Director, Biology
A biochemist, Dr. Barbaras has an extensive background in HDL research, including lipoprotein binding and cholesterol synthesis. Dr. Barbaras was formerly the Director of Research and group leader in ATP synthase, HDL metabolism and immunomodulation at Institut National de la Santé et de la Recherche Médicale (INSERM), the French public research institution dedicated to biological, medical and public health research.